Excellent proliferation and persistence of allogeneic donor-derived 41-BB based CAR-T cells despite immunosuppression with cyclosporine A
- 1 June 2020
- journal article
- editorial
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 105 (6), E322-E324
- https://doi.org/10.3324/haematol.2019.245969
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Posttransplant chimeric antigen receptor therapyBlood, 2018
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaThe New England Journal of Medicine, 2018
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaThe New England Journal of Medicine, 2017
- Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adultsBlood, 2017
- Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activityNature Medicine, 2017
- Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cellsJCI Insight, 2016
- Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host DiseaseJournal of Clinical Oncology, 2016
- Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemiaOncoImmunology, 2015
- The effects of Cyclosporine A and azathioprine on human T cells activated by different costimulatory signalsImmunology Letters, 2011
- Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myelomaLeukemia, 2003